Extracellular vesicles in hematological malignancies: EV-dence for reshaping the tumoral microenvironment.
cellular communication
exosomes
extracellular vesicles
hematological malignancies
leukemia
microenvironment
microparticles
multiple myeloma
Journal
Frontiers in immunology
ISSN: 1664-3224
Titre abrégé: Front Immunol
Pays: Switzerland
ID NLM: 101560960
Informations de publication
Date de publication:
2023
2023
Historique:
received:
24
07
2023
accepted:
04
09
2023
medline:
1
11
2023
pubmed:
12
10
2023
entrez:
12
10
2023
Statut:
epublish
Résumé
Following their discovery at the end of the 20th century, extracellular vesicles (EVs) ranging from 50-1,000 nm have proven to be paramount in the progression of many cancers, including hematological malignancies. EVs are a heterogeneous group of cell-derived membranous structures that include small EVs (commonly called exosomes) and large EVs (microparticles). They have been demonstrated to participate in multiple physiological and pathological processes by allowing exchange of biological material (including among others proteins, DNA and RNA) between cells. They are therefore a crucial way of intercellular communication. In this context, malignant cells can release these extracellular vesicles that can influence their microenvironment, induce the formation of a tumorigenic niche, and prepare and establish distant niches facilitating metastasis by significantly impacting the phenotypes of surrounding cells and turning them toward supportive roles. In addition, EVs are also able to manipulate the immune response and to establish an immunosuppressive microenvironment. This in turn allows for ideal conditions for heightened chemoresistance and increased disease burden. Here, we review the latest findings and reports studying the effects and therapeutic potential of extracellular vesicles in various hematological malignancies. The study of extracellular vesicles remains in its infancy; however, rapid advances in the analysis of these vesicles in the context of disease allow us to envision prospects to improve the detection and treatment of hematological malignancies.
Identifiants
pubmed: 37822925
doi: 10.3389/fimmu.2023.1265969
pmc: PMC10562589
doi:
Types de publication
Journal Article
Review
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
1265969Informations de copyright
Copyright © 2023 Van Morckhoven, Dubois, Bron, Meuleman, Lagneaux and Stamatopoulos.
Déclaration de conflit d'intérêts
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Références
Blood. 2014 Dec 11;124(25):3748-57
pubmed: 25320245
Diagnostics (Basel). 2021 May 21;11(6):
pubmed: 34063765
Int J Oncol. 2021 Feb;58(2):238-250
pubmed: 33491750
J Pathol. 2022 Apr;256(4):402-413
pubmed: 34919276
J Transl Med. 2022 Jan 3;20(1):6
pubmed: 34980158
Int J Mol Sci. 2021 Nov 09;22(22):
pubmed: 34829995
Front Oncol. 2021 Dec 21;11:779567
pubmed: 34993140
Stem Cells Int. 2017;2017:9012152
pubmed: 29333170
Medicine (Baltimore). 2021 Jan 29;100(4):e23447
pubmed: 33530159
Cells. 2019 May 27;8(5):
pubmed: 31137912
Hum Cell. 2020 Jul;33(3):599-609
pubmed: 32281045
Carcinogenesis. 2020 Mar 13;41(1):100-110
pubmed: 31586190
Leukemia. 2020 Apr;34(4):966-984
pubmed: 32127639
Front Immunol. 2019 Jan 15;9:3164
pubmed: 30697216
Leukemia. 2018 Mar;32(3):575-587
pubmed: 28816238
JCI Insight. 2019 Nov 1;4(21):
pubmed: 31593552
Nucleic Acids Res. 2012 Oct;40(18):9272-85
pubmed: 22821563
Elife. 2019 Feb 05;8:
pubmed: 30720426
Int J Nanomedicine. 2019 Aug 26;14:6843-6854
pubmed: 31692567
Philos Trans R Soc Lond B Biol Sci. 2014 Sep 26;369(1652):
pubmed: 25135963
Mol Ther. 2020 Nov 4;28(11):2358-2366
pubmed: 32931751
Front Cell Dev Biol. 2021 Aug 03;9:643043
pubmed: 34414175
Front Cell Dev Biol. 2020 Nov 16;8:581882
pubmed: 33304899
Leukemia. 2018 May;32(5):1180-1188
pubmed: 29479064
Blood Adv. 2019 Nov 12;3(21):3228-3240
pubmed: 31698453
Proc Natl Acad Sci U S A. 2014 Aug 5;111(31):E3234-42
pubmed: 24938788
Blood. 1998 Apr 1;91(7):2387-96
pubmed: 9516138
Proc Natl Acad Sci U S A. 2012 Mar 13;109(11):4146-51
pubmed: 22315426
Front Oncol. 2020 Aug 19;10:1422
pubmed: 32974152
Oncotarget. 2018 Apr 27;9(32):22850-22861
pubmed: 29854319
Biochem Biophys Res Commun. 2022 Sep 24;622:149-156
pubmed: 35863089
Blood Adv. 2022 Mar 22;6(6):1879-1894
pubmed: 35130345
Int J Oncol. 2019 Mar;54(3):1061-1070
pubmed: 30664188
Cell Commun Signal. 2015 Feb 03;13:8
pubmed: 25644060
Stem Cell Res Ther. 2019 Dec 16;10(1):384
pubmed: 31842997
Front Pharmacol. 2021 Sep 13;12:728916
pubmed: 34588984
Br J Haematol. 2019 Jun;185(5):987-991
pubmed: 30450539
Sci Immunol. 2017 Jul 28;2(13):
pubmed: 28754746
Cancers (Basel). 2020 May 14;12(5):
pubmed: 32422889
Leukemia. 2021 Jul;35(7):1925-1932
pubmed: 33139859
Exp Hematol. 2019 Aug;76:60-66.e2
pubmed: 31369790
Blood Adv. 2023 Apr 11;7(7):1190-1203
pubmed: 36044386
Blood. 2015 May 21;125(21):3297-305
pubmed: 25833959
Curr Biol. 2009 Dec 1;19(22):1875-85
pubmed: 19896381
J Extracell Vesicles. 2021 Nov;10(13):e12168
pubmed: 34807526
J Proteomics. 2016 Mar 16;136:89-98
pubmed: 26775013
Chem Immunol Allergy. 2014;99:180-96
pubmed: 24217610
BMC Genomics. 2013 May 10;14:319
pubmed: 23663360
Mol Med. 2015 Jan 09;21:123-33
pubmed: 25584781
Oncogene. 2019 Jun;38(26):5227-5238
pubmed: 30890754
Anticancer Drugs. 2021 Sep 1;32(8):802-811
pubmed: 33853086
J Clin Invest. 2013 Apr;123(4):1542-55
pubmed: 23454749
Mol Carcinog. 2023 Jun;62(6):743-753
pubmed: 36825759
Br J Haematol. 1967 May;13(3):269-88
pubmed: 6025241
J Extracell Vesicles. 2020 May 26;9(1):1764213
pubmed: 32944168
Tumour Biol. 2015 Dec;36(12):9739-52
pubmed: 26156801
Lancet. 2018 Aug 18;392(10147):593-606
pubmed: 30078459
Cancer Sci. 2020 Aug;111(8):2726-2735
pubmed: 32437078
Nat Cell Biol. 2012 Jun 03;14(7):677-85
pubmed: 22660413
Aging (Albany NY). 2021 Apr 23;13(10):13644-13662
pubmed: 33893245
Front Immunol. 2022 Jul 07;13:909880
pubmed: 35874665
Onco Targets Ther. 2021 Jan 15;14:455-467
pubmed: 33488100
Cancer. 1981 Jul 1;48(1):198-206
pubmed: 7237385
J Clin Invest. 2021 Jan 4;131(1):
pubmed: 33108353
Cell Oncol (Dordr). 2020 Oct;43(5):889-900
pubmed: 32578140
J Cell Mol Med. 2016 Oct;20(10):1829-39
pubmed: 27196940
Front Immunol. 2014 Apr 10;5:160
pubmed: 24782865
Sci Signal. 2016 Sep 06;9(444):ra88
pubmed: 27601730
Front Oncol. 2022 Jun 21;12:860849
pubmed: 35800053
BMC Cancer. 2021 Sep 7;21(1):1002
pubmed: 34493241
Int J Mol Sci. 2022 Nov 08;23(22):
pubmed: 36430163
Vaccine. 2019 Mar 7;37(11):1377-1383
pubmed: 30755368
Oncotarget. 2015 May 10;6(13):11378-94
pubmed: 25869099
Nat Rev Dis Primers. 2017 Jul 20;3:17046
pubmed: 28726797
Blood Cancer Discov. 2023 Jan 6;4(1):54-77
pubmed: 36108149
Blood. 2016 Jul 28;128(4):542-52
pubmed: 27118451
J Transl Med. 2021 Dec 18;19(1):511
pubmed: 34922585
Cancer Biomark. 2020;28(2):151-158
pubmed: 32176633
Blood. 1975 Aug;46(2):219-34
pubmed: 1139039
Mol Cancer. 2020 Nov 12;19(1):160
pubmed: 33183286
Acta Neuropathol. 2015 May;129(5):695-713
pubmed: 25778619
Cell Commun Signal. 2021 Apr 23;19(1):47
pubmed: 33892745
J Pathol. 2019 Feb;247(2):241-253
pubmed: 30357841
Blood. 2000 Oct 15;96(8):2655-63
pubmed: 11023495
Oncotarget. 2017 Mar 22;8(31):50949-50957
pubmed: 28881619
Br J Haematol. 2020 Oct;191(2):152-170
pubmed: 32196650
Epigenomics. 2019 Jan;11(1):35-51
pubmed: 30211623
Mol Cancer. 2022 Dec 22;21(1):226
pubmed: 36550553
J Extracell Vesicles. 2019 Feb 11;8(1):1573051
pubmed: 30788083
Int J Mol Sci. 2019 Jul 01;20(13):
pubmed: 31266187
Front Med (Lausanne). 2021 Dec 16;8:793040
pubmed: 34977093
J Extracell Vesicles. 2013 Sep 12;2:
pubmed: 24223256
Cells. 2022 Oct 25;11(21):
pubmed: 36359760
Iran J Pharm Res. 2021 Winter;20(1):384-397
pubmed: 34400967
Biochem Soc Trans. 2013 Feb 1;41(1):245-51
pubmed: 23356291
Nat Rev Mol Cell Biol. 2018 Apr;19(4):213-228
pubmed: 29339798
Leukemia. 2017 Apr;31(4):985-988
pubmed: 28008175
Ann Hematol. 2014 Oct;93(10):1735-43
pubmed: 24858372
Leuk Res. 2021 Jun;105:106566
pubmed: 33848709
Int J Nanomedicine. 2021 May 07;16:3141-3160
pubmed: 33994784
J Leukoc Biol. 2022 Jul;112(1):31-45
pubmed: 35674096
Proteomics. 2021 Jul;21(13-14):e2000119
pubmed: 33580572
Stem Cell Rev Rep. 2017 Dec;13(6):817-825
pubmed: 28918518
Cancers (Basel). 2020 Feb 14;12(2):
pubmed: 32075123
Theranostics. 2022 Mar 21;12(6):2894-2907
pubmed: 35401837
Blood Adv. 2022 Apr 26;6(8):2480-2495
pubmed: 34979567
Lancet. 2021 Jan 30;397(10272):410-427
pubmed: 33516340
J Clin Haematol. 2021;2(2):36-39
pubmed: 34296216
Cancer Lett. 2014 Jun 28;348(1-2):71-6
pubmed: 24657661
Nat Cell Biol. 2019 Jul;21(7):856-866
pubmed: 31235936
Cell Signal. 2021 Feb;78:109872
pubmed: 33290841
Blood. 2017 Apr 27;129(17):2429-2436
pubmed: 28213378
Mol Cell Probes. 2020 Jun;51:101513
pubmed: 31968218
Proc Natl Acad Sci U S A. 2016 Feb 23;113(8):E968-77
pubmed: 26858453
Haematologica. 2017 Sep;102(9):1594-1604
pubmed: 28596280
Sci Rep. 2022 Jul 13;12(1):11975
pubmed: 35831551
Oncotarget. 2015 Dec 22;6(41):43992-4004
pubmed: 26556857
Cell Death Dis. 2022 Jan 28;13(1):92
pubmed: 35091542
J Nanobiotechnology. 2022 Jan 10;20(1):29
pubmed: 35012554
Hematol Oncol. 2021 Aug;39(3):390-400
pubmed: 33969901
Am J Transl Res. 2016 Sep 15;8(9):3614-3629
pubmed: 27725845
Ann Hematol. 2021 May;100(5):1355-1356
pubmed: 32474620
Endocr J. 2021 Oct 28;68(10):1197-1208
pubmed: 34039781
J Exp Clin Cancer Res. 2021 Feb 1;40(1):49
pubmed: 33522952
Cancers (Basel). 2019 Nov 20;11(12):
pubmed: 31756922
Chin Med J (Engl). 2020 Dec 5;133(23):2829-2839
pubmed: 33273332
J Cell Mol Med. 2022 Aug;26(16):4566-4576
pubmed: 35822529
Front Cell Dev Biol. 2022 Mar 01;10:862524
pubmed: 35300408
Cancer Lett. 2022 Jun 1;535:215649
pubmed: 35315341
J Biol Chem. 1998 Aug 7;273(32):20121-7
pubmed: 9685355
J Immunol. 2009 Sep 15;183(6):3720-30
pubmed: 19692638
Hematol Oncol. 2019 Oct;37(4):409-417
pubmed: 31102419
J Orthop Surg Res. 2021 Oct 24;16(1):637
pubmed: 34689803
Blood. 2015 Aug 27;126(9):1106-17
pubmed: 26100252
Nat Nanotechnol. 2021 Jul;16(7):748-759
pubmed: 34211166
Blood. 2002 Mar 1;99(5):1536-43
pubmed: 11861265
J Pers Med. 2021 Nov 23;11(12):
pubmed: 34945712
Ann Hematol. 2019 Mar;98(3):595-603
pubmed: 30673813
Annu Rev Biochem. 2019 Jun 20;88:487-514
pubmed: 31220978
J Pathol. 2016 Jun;239(2):162-73
pubmed: 26956697
J Biochem. 2020 Nov 1;168(5):491-498
pubmed: 32770182
J Extracell Vesicles. 2018 Nov 23;7(1):1535750
pubmed: 30637094
Hematology Am Soc Hematol Educ Program. 2016 Dec 2;2016(1):580-588
pubmed: 27913532
Hum Gene Ther. 2021 Oct;32(19-20):1224-1241
pubmed: 34494460
Acta Pharmacol Sin. 2017 Nov;38(11):1475-1485
pubmed: 28836580
Haematologica. 2011 Sep;96(9):1302-9
pubmed: 21606166
Genome Biol. 2015 Jan 29;16:18
pubmed: 25723320
Asian J Pharm Sci. 2022 May;17(3):462-474
pubmed: 35782327
Trends Cancer. 2020 Nov;6(11):910-923
pubmed: 32660885
Exp Hematol Oncol. 2021 Mar 31;10(1):24
pubmed: 33789743
J Cell Physiol. 2019 Jul;234(7):10602-10614
pubmed: 30417360
Nano Lett. 2023 Feb 22;23(4):1591-1599
pubmed: 36723485
Cancer Res. 2020 Sep 1;80(17):3663-3676
pubmed: 32605996
Haematologica. 2022 Sep 01;107(9):2183-2194
pubmed: 35263984
Theranostics. 2021 Jan 1;11(5):2364-2380
pubmed: 33500730
Med J Aust. 2019 May;210(8):375-380
pubmed: 31012120
Cancer Gene Ther. 2022 Jul;29(7):918-929
pubmed: 34453123
Front Oncol. 2022 Mar 16;12:824562
pubmed: 35371979
Blood Adv. 2017 May 16;1(13):812-823
pubmed: 29296725
Nat Commun. 2019 Sep 25;10(1):4355
pubmed: 31554797
Cells. 2022 Jul 12;11(14):
pubmed: 35883619
Curr Oncol Rep. 2021 Apr 14;23(6):66
pubmed: 33855607
Life Sci. 2019 Mar 15;221:187-195
pubmed: 30716336
Blood Cancer J. 2018 Jan 12;8(1):7
pubmed: 29330358
BMJ. 2021 Oct 6;375:n2026
pubmed: 34615640
Semin Cancer Biol. 2014 Oct;28:3-13
pubmed: 24769058
Theranostics. 2019 Jul 28;9(19):5642-5656
pubmed: 31534508
Cancer Cell. 2020 Jun 8;37(6):867-882.e12
pubmed: 32470390
Blood Rev. 2022 Jul;54:100930
pubmed: 35151528
Am J Hematol. 2019 Nov;94(11):1266-1287
pubmed: 31364186
J Exp Med. 1996 Mar 1;183(3):1161-72
pubmed: 8642258
Crit Rev Clin Lab Sci. 2018 Nov;55(7):501-515
pubmed: 30238808
Br J Haematol. 2021 Nov;195(3):399-404
pubmed: 34318932
Blood. 2013 May 2;121(18):3658-65
pubmed: 23509156
Cytotherapy. 2019 Jan;21(1):96-106
pubmed: 30409700
Front Oncol. 2020 Feb 14;10:90
pubmed: 32117744
Stem Cells Int. 2020 Dec 13;2020:8890201
pubmed: 33414831
Blood. 2000 Sep 15;96(6):2240-5
pubmed: 10979972
J Cell Physiol. 2019 Apr;234(4):3697-3710
pubmed: 30317554
Lancet Oncol. 2016 Jun;17(6):779-790
pubmed: 27185642
Cell Death Dis. 2022 Apr 12;13(4):337
pubmed: 35414137
Cancers (Basel). 2021 Mar 19;13(6):
pubmed: 33808645
Cell Physiol Biochem. 2017;44(1):240-254
pubmed: 29130994
Mol Med. 2021 Oct 16;27(1):128
pubmed: 34656078
J Immunother Cancer. 2021 Apr;9(4):
pubmed: 33931471
PLoS Genet. 2021 Dec 6;17(12):e1009951
pubmed: 34871319
Cell Biosci. 2022 Mar 28;12(1):37
pubmed: 35346363
Lancet. 2020 Apr 4;395(10230):1146-1162
pubmed: 32247396
Anticancer Res. 2018 Jul;38(7):3935-3942
pubmed: 29970515
Hum Cell. 2021 May;34(3):965-976
pubmed: 33620671
Front Cell Dev Biol. 2021 Oct 01;9:734950
pubmed: 34660591
Oncol Lett. 2020 Oct;20(4):31
pubmed: 32774504
Carcinogenesis. 2017 Jul 1;38(7):708-716
pubmed: 28838065
Oncoimmunology. 2020 Jun 23;9(1):1782575
pubmed: 32923146
Cancers (Basel). 2020 Aug 04;12(8):
pubmed: 32759820
Mol Cancer. 2021 Jan 11;20(1):13
pubmed: 33430880
Cell Oncol (Dordr). 2017 Feb;40(1):97-103
pubmed: 27761889
Am J Hematol. 2020 Dec;95(12):1599-1613
pubmed: 32974939
Blood Cancer J. 2018 Nov 8;8(11):105
pubmed: 30409995
J Cancer. 2022 Feb 21;13(5):1388-1397
pubmed: 35371331